Deekshita Ramanarayanan

Nov 27, 2024 | newsecuritybeat.org | Deekshita Ramanarayanan

Over the last four decades, contracting HIV has been transformed from a fatal diagnosis to a manageable chronic illness. Political will and financial commitments have reduced . However, much work still is needed to meet global targets of preventing new cases of HIV and reducing AIDS-related deaths. Marginalized communities, including women and girls, face countless barriers which hinder progress towards comprehensive HIV prevention across the planet.

Nov 20, 2024 | newsecuritybeat.org | Deekshita Ramanarayanan

By Maternal health among adolescents in low- and middle-income countries (LMICs) remains a largely unexplored and frequently neglected area within the public health field. Adolescent birth rates remain disproportionately high in LMICs, accounting for approximately 97% of all adolescent births globally.

Sep 4, 2024 | newsecuritybeat.org | Deekshita Ramanarayanan

By Two years ago, the World Health Organization (WHO) declared a public health emergency after a multi-country outbreak of mpox (formerly known as monkeypox). Now, in the summer of 2024, mpox is on the rise again. On August 14, The WHO declared a new public health emergency due to a recent outbreak in the Democratic Republic of the Congo (DRC) and other African countries.

Aug 28, 2024 | wilsoncenter.org | Sarah Barnes |Claire Doyle |Deekshita Ramanarayanan

ClimateReproductive HealthGender EqualityA warming world is leading to new challenges for communities and countries around the globe. The significant impacts of climate change on global health, and on women and girls, are well-documented. Yet despite the evidence, funding for climate responses that focus on health or gender remains relatively low.

Jul 10, 2024 | newsecuritybeat.org | Deekshita Ramanarayanan

Last month, the biopharmaceutical company Gilead shared groundbreaking results from a recent clinical trial (PURPOSE1) for long-acting injectable HIV prevention. The twice-yearly injectable drug, lenacapavir, provided total protection from HIV for a test group of 2,134 women in Uganda and South Africa. While lenacapavir has been used to treat multi-drug resistant HIV since 2022, this trial marks the first usage as pre-exposure prophylaxis (PrEP).